Rigel Pharmaceuticals | RIGL - Assets


Rigel Pharmaceuticals reported $242.53M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Celldex Therapeutics USD 782.35M 271.09M Jun/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Veracyte USD 1.49B 49.97M Jun/2026